{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:05:10Z","timestamp":1784005510702,"version":"3.55.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cancer is a significant cause of mortality in kidney transplant recipients (KTr). Specifically, the relationship between cancer and kidney transplantation (KTx) is evident from the initial evaluation of CKD patients prior to their placement on the KTx waiting list. After KTx, a significant impact on the potential development of cancer is linked to immunosuppressive therapies, necessary to maintain renal function post-KTx, and to complications, especially infectious ones, typical of these patients. Ultimately, once cancer is diagnosed in a KTx, nephrologists and transplant specialists are forced to modulate suppressive therapies and, together with oncologists, manage specific cancer treatment therapies. In this highly complex scenario, unfortunately, there are few certainties, and they are limited to a few studies, often involving a small number of patients. This review integrates current data on risk, prevention, and treatment across the entire pathway: pre-transplant assessment, post-transplant surveillance, and management after a cancer diagnosis. A special focus will be reserved to the new evidences regarding the treatment with immune-checkpoint inhibitors (ICIs).<\/jats:p>","DOI":"10.3389\/fimmu.2026.1778752","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:21:53Z","timestamp":1784002913000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Onco-nephrology in kidney transplant recipients: challenges and evolving strategies"],"prefix":"10.3389","volume":"17","author":[{"given":"Carlo","family":"Alfieri","sequence":"first","affiliation":[{"name":"Unit of Nephrology, Dialysis and Kidney Transplantation, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico di Milano","place":["Milan, Italy"]},{"name":"Department of Clinical Sciences and Community Health, Dipartimento di Eccellenza, University of Milan","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariadelina","family":"Simeoni","sequence":"additional","affiliation":[{"name":"Department of Translation Medical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Di Naro","sequence":"additional","affiliation":[{"name":"Unit of Nephrology, Dialysis and Kidney Transplantation, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico di Milano","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Mattinzoli","sequence":"additional","affiliation":[{"name":"Renal Research Laboratory, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Ikehata","sequence":"additional","affiliation":[{"name":"Renal Research Laboratory, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Armelloni","sequence":"additional","affiliation":[{"name":"Renal Research Laboratory, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Molinari","sequence":"additional","affiliation":[{"name":"Unit of Nephrology, Dialysis and Kidney Transplantation, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico di Milano","place":["Milan, Italy"]},{"name":"Department of Clinical Sciences and Community Health, Dipartimento di Eccellenza, University of Milan","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Maggi","sequence":"additional","affiliation":[{"name":"Unit of Nephrology, Dialysis and Kidney Transplantation, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico di Milano","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Mella","sequence":"additional","affiliation":[{"name":"Division of Nephrology Dialysis and Renal Transplantation - \u201cCitt\u00e0 della Salute e della Scienza\u201d University Hospital","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Regalia","sequence":"additional","affiliation":[{"name":"Unit of Nephrology, Dialysis and Kidney Transplantation, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico di Milano","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Verdesca","sequence":"additional","affiliation":[{"name":"Unit of Nephrology, Dialysis and Kidney Transplantation, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico di Milano","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evaldo","family":"Favi","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, Dipartimento di Eccellenza, University of Milan","place":["Milan, Italy"]},{"name":"General Surgery and Kidney Transplantation, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cosmai","sequence":"additional","affiliation":[{"name":"UOC Nephrology and Dialysis, Azienda Socio-Sanitaria Territoriale (ASST) Fatebenefratelli-Sacco, Fatebenefratelli Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Messa","sequence":"additional","affiliation":[{"name":"Unit of Nephrology, Dialysis and Kidney Transplantation, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico di Milano","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Castellano","sequence":"additional","affiliation":[{"name":"Unit of Nephrology, Dialysis and Kidney Transplantation, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico di Milano","place":["Milan, Italy"]},{"name":"Department of Clinical Sciences and Community Health, Dipartimento di Eccellenza, University of Milan","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2024.108161","article-title":"Cancer mortality among solid organ transplant recipients: a systematic review and meta-analysis","volume":"189","author":"Wang","year":"2024","journal-title":"Prev Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181caeead","article-title":"Reduction in cardiovascular death after kidney transplantation","volume":"89","author":"Pilmore","year":"2010","journal-title":"Transplantation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res Integr Peer Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf084","article-title":"Incidence of cancer in people with CKD not requiring kidney replacement therapy: a systematic review and meta-analysis","volume":"18","author":"Elyan","year":"2025","journal-title":"Clin Kidney J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa122","article-title":"Oncogenic mechanisms in renal insufficiency","volume":"14","author":"Volovat","year":"2020","journal-title":"Clin Kidney J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40620-018-0542-y","article-title":"Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelines","volume":"32","author":"Frasc\u00e0","year":"2019","journal-title":"J Nephrol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/TP.0000000000003136","article-title":"KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation","volume":"104","author":"Chadban","year":"2020","journal-title":"Transplantation"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1629521","article-title":"Pre-existing oncohematological disease in kidney transplant recipients: impact on graft survival, acute rejection, and long-term clinical outcomes","volume":"16","author":"Mella","year":"2025","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29174156","article-title":"Bio-Pathological Functions of Posttranslational Modifications of Histological Biomarkers in Breast Cancer","volume":"29","author":"Neagu","year":"2024","journal-title":"Molecules"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000005056","article-title":"Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion","volume":"108","author":"Watt","year":"2024","journal-title":"Transplantation"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2022.11.006","article-title":"Mortality among solid organ transplant recipients with a pretransplant cancer diagnosis","volume":"23","author":"Hart","year":"2023","journal-title":"Am J Transplant"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-020-00775-4","article-title":"Donor-transmitted cancer in kidney transplant recipients: a systematic review","volume":"33","author":"Eccher","year":"2020","journal-title":"J Nephrol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000004117","article-title":"Malignancies in Deceased Organ Donors: The Spanish Experience","volume":"106","author":"Mah\u00edllo","year":"2022","journal-title":"Transplantation"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767080-00006","article-title":"Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review","volume":"67","author":"Gutierrez-Dalmau","year":"2007","journal-title":"Drugs"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.23876\/j.krcp.18.0063","article-title":"Common viral infections in kidney transplant recipients","volume":"37","author":"Vanichanan","year":"2018","journal-title":"Kidney Res Clin Pract"},{"key":"B16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/11203990-000000000-00000","article-title":"Basiliximab: a review of its use as induction therapy in renal transplantation","volume":"24","author":"McKeage","year":"2010","journal-title":"BioDrugs"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw368","article-title":"Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects","volume":"32","author":"Bamoulid","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13092","article-title":"ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients","volume":"15","author":"Crepin","year":"2015","journal-title":"Am J Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2025.01.035","article-title":"Risk and prognosis of posttransplant lymphoproliferative disease in Epstein-Barr virus-seronegative kidney transplant recipients - an observational cohort study from Norway and western Denmark","volume":"25","author":"Ludvigsen","year":"2025","journal-title":"Am J Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2024.13220","article-title":"Post-Kidney Transplant Cancer: A Real-World Retrospective Analysis From a Single Italian Center","volume":"37","author":"Re Sart\u00f2","year":"2024","journal-title":"Transpl Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw088","article-title":"Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients","volume":"31","author":"Opelz","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26083736","article-title":"The Role of microRNAs in Lung Cancer: Mechanisms, Diagnostics and Therapeutic Potential","volume":"26","author":"Bartoszewska","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091442","article-title":"Liquid Biopsy as a New Tool for Diagnosis and Monitoring in Renal Cell Carcinoma","volume":"17","author":"Netti","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1186\/s12967-025-07030-z","article-title":"MicroRNA signatures of cancer risk in kidney transplant patients: insights from the COMETA study","volume":"23","author":"Simeoni","year":"2025","journal-title":"J Transl Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation","volume":"367","author":"Euvrard","year":"2012","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.6691","article-title":"Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results","volume":"36","author":"Dantal","year":"2018","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s40472-025-00481-9","article-title":"Current Use of Belatacept in Kidney Transplantation: A Review of Historical Use and Modern Trends","volume":"12","author":"Di Maria","year":"2025","journal-title":"Curr Transpl Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/genes16040391","article-title":"Toxoplasma Gondii Replication During Belatacept Treatment in Kidney Transplantation: A Case Report and a Review of the Literature","volume":"16","author":"Vigilante","year":"2025","journal-title":"Genes (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000411","article-title":"Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients","volume":"19","author":"Divard","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/frtra.2023.1280993","article-title":"Post-transplant lymphoproliferative disorder risk and outcomes in renal transplant patients treated with belatacept immunosuppression","volume":"2","author":"Koff","year":"2024","journal-title":"Front Transplant"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.05.068","article-title":"De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy","volume":"91","author":"Jew","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1186\/s12882-025-04373-z","article-title":"Belatacept and non-melanoma skin cancer risk in kidney transplant recipients: a narrative review from a mechanistic and clinical perspective","volume":"26","author":"El Hennawy","year":"2025","journal-title":"BMC Nephrol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2025.03.004","article-title":"Real-world evidence regarding cancer, mortality, and graft failure risk with de novo belatacept use among kidney transplant recipients in the United States","volume":"25","author":"Ahmed","year":"2025","journal-title":"Am J Transplant"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03914.x","article-title":"Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys","volume":"12","author":"Pestana","year":"2012","journal-title":"Am J Transplant"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8122189","article-title":"Management of Immunosuppression in Kidney Transplant Recipients Who Develop Malignancy","volume":"8","author":"Yang","year":"2019","journal-title":"J Clin Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2024.13322","article-title":"Immune Checkpoint Inhibitor Therapy for Kidney Transplant Recipients - A Review of Potential Complications and Management Strategies","volume":"37","author":"Barbir","year":"2024","journal-title":"Transpl Int"},{"key":"B38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.kint.2024.09.017","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology","volume":"107","author":"Herrmann","year":"2025","journal-title":"Kidney Int"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1353339","article-title":"Immune checkpoint inhibitors and acute kidney injury","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00368-0","article-title":"Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study","volume":"23","author":"Carroll","year":"2022","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01497","article-title":"Nivolumab + Tacrolimus + Prednisone \u00b1 Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers","volume":"42","author":"Schenk","year":"2024","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01498","article-title":"Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma","volume":"42","author":"Hanna","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1778752\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:21:54Z","timestamp":1784002914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1778752\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2026.1778752"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1778752","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"article-number":"1778752"}}